Overview

Decitabine for Poor Graft Function Post Allo-HSCT

Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Treatments:
Decitabine
Epoetin Alfa
Lenograstim